Shots:

• The P-II HERTHENA-Lung01 study involves assessing patritumab deruxtecan in 420 patients in a ratio (1:1) with EGFR-mutated m/ LA NSCLC prior treated with TKI and Pt-based CT. The first patient has been dosed in P-II study
• The 1EPs of P-II study include ORR and 2EPs include DoR- PFS- DCR- and time to response. Moreover- the level of HER3 protein expression in tumor tissue and its relationship with efficacy will be analyzed along with its PK and immunogenicity
• Patritumab deruxtecan is an investigational ADC and is comprised of a human anti-HER3 Ab attached to a topoisomerase I inhibitor payload via a stable tetrapeptide-based cleavable linker

 ­ Ref: Businesswire | Image: Medical Dialogues